Prosonix launches laboratory scale sonocrystallisation development suite

Prosonix, of Oxford in the UK, launched a suite of manual, semi-automated, and fully automated sonocrystallisation equipment.

Sonocrystallisation technology allows chemists to control particle size, morphology and polymorphism, resulting in higher quality crystalline materials with improved physicochemical properties and formulation performance. Designed for use in our clients" own laboratories, the three new systems span the full pharmaceutical life cycle from discovery to market.

SonoLab Discovery is intended for parallel screening activities. It introduces development chemists to hands-on sonocrystallisation and will speed up the evaluation of new compounds at a 50ml scale.

SonoLab Research is a more sophisticated system for process research involving batches up to 2 litres, whether continuous or continuous with recirculation.

SonoLab Development uses a larger reactor and can be used in conjunction with pilot scale 10-20 litre reactors.

As a whole, the SonoLab suite provides a powerful tool for real-time in-situ control of nucleation and by manipulation offers a tailored particle engineering solution. All three systems are based on Prosonix's successful pharmaceutical industrialisation of sonocrystallisation and can be linked to on-line analytical techniques such as Raman, FBRM, and turbidity.

"The launch of the SonoLab suite is a natural extension of the provision of our unique sonocrystallisation solutions," said David Hipkiss, Prosonix ceo. "Using any of the systems enables a seamless transition into the proven Prosonitron range of commercial scale sonoprocessing reactors. This gives a high degree of assurance that positive results can be readily replicated at commercial scale.